Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: A randomized, double-blind comparison

Journal of Dermatological Treatment

Volumn 17, Issue 1, 2006, Pages 38-44

  Sigurgeirsson, Bardur ^a,e   Elewski, Boni E ^b   Rich, Phoebe A ^c   Opper, Carol ^d   Cai, Bin ^d   Nyirady, Judit ^d   Bakshi, Rajesh ^d  

^a UNIVERSITY OF ICELAND   (Iceland)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Northwest Cutaneous Research Specialists   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Novartis Pharma AG ^*  (Iceland)

Author keywords

Clinical trial; Efficacy; Intermittent; Onychomycosis; Pulsed dose; Terbinafine; Tolerability

Indexed keywords

LIVER ENZYME; TERBINAFINE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHYTE; DIARRHEA; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; STOMACH HEMORRHAGE; TASTE DISORDER; TOENAIL ONYCHOMYCOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; ONYCHOMYCOSIS; TREATMENT OUTCOME;

EID: 32644465979     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630500504713     Document Type: Article

References (23)

1. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43(2 Pt 1):244-8.
2. Baran R, Hay RJ, Tosti A, et al. A new classification of onychomycosis. Br J Dermatol. 1998;139:567-71.
3. Elewski BE, Leyden J, Rinaldi MG, et al. Office practice-based confirmation of onychomycosis: a US nationwide prospective survey. Arch Intern Med. 2002;162:2133-8.
4. Jarv H, Naaber P, Kaur S, et al. Toenail onychomycosis in Estonia. Mycoses. 2004;47(1-2):57-61.
5. Gupta AK, Ryder JE, Skinner AR. Treatment of onychomycosis: pros and cons of antifungal agents. J Cutan Med Surg. 2004;8:25-30.
6. Lagana FJ. Curing onychomycosis: understanding the multitude of variables. Clin Podiatr Med Surg. 2004;21:555-64, vi.
7. Roujeau JC, Sigurgeirsson B, Korting HC, et al. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology. 2004;209:301-7.
8. Joseph WS. The oral antifungal patient. Clin Podiatr Med Surg. 2004;21:591-604, vii.
9. Darkes MJ, Scott LJ, Goa KL. Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol. 2003;4:39-65.
10. De Cuyper C, Hindryckx PH. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol. 1999;141(suppl 56):15-20.
11. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol. 2004;150:537-44.
12. Heikkila H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafme or itraconazole. Br J Dermatol. 2002;146:250-3.
13. Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138:353-7.
14. Brautigam M, Nolting S, Schopf RE, et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ. 1995;311:919-22.
15. De Backer M, De Vroey C, Lesaffre E, et al. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol. 1998;38(5 Pt 3):S57-63.
16. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafme compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ. 1999;318:1031-5.
17. Gupta AK, Schouten JR, Tavakkol A. Critical review of efficacy of pulse therapy regimens using terbinafine to treat dermatophyte toenail onychomycosis. Poster presented at AAD 2005, New Orleans, USA; 2005.
18. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafme for dermatophyte toe-onychomycosis: a new approach. J Dermatol. 1996;23:259-62.
19. Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafme treatment and intermittent itraconazole therapy. J Am Acad Dermatol. 1996;34:595-600.
20. Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafme pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol. 2001;44:485-91.
21. Zaias N, Rebell G. The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine. Arch Dermatol. 2004;140:691-5.
22. Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol. 1997;37(5 Pt 1):740-5.
23. Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse vs continuous terbinafine for onychomycosis: Results of a double-blind controlled trial. J Am Acad Dermatol. 2005;53:578-84.